{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:17:04Z","timestamp":1791818224211,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11427-024-2974-3","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T07:48:40Z","timestamp":1761378520000},"page":"214-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The characteristics and prognostic analysis of therapy-related acute myeloid leukemia patients in China"],"prefix":"10.1007","volume":"69","author":[{"given":"Feifei","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2974_CR1","first-page":"16344","volume":"133","author":"M Adamska","year":"2023","unstructured":"Adamska, M., Kowal-Wi\u015bniewska, E., Przyby\u0142owicz-Chalecka, A., Bara\u0144ska, M., \u0141ojko-Dankowska, A., Joks, M., Kandu\u0142a, Z., Jarmu\u017c-Szymczak, M., and Gil, L. (2023). Clinical outcomes of therapy-related acute myeloid leukemia: over 20 years long single center retrospective analysis. Polish Arch Internal Med 133, 16344.","journal-title":"Polish Arch Internal Med"},{"key":"2974_CR2","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00277-023-05356-6","volume":"102","author":"H Araie","year":"2023","unstructured":"Araie, H., Arai, Y., Kida, M., Aoki, J., Uchida, N., Doki, N., Fukuda, T., Tanaka, M., Ozawa, Y., Sawa, M., et al. (2023). Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy. Ann Hematol 102, 2879\u20132893.","journal-title":"Ann Hematol"},{"key":"2974_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M., and Vardiman, J.W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391\u20132405.","journal-title":"Blood"},{"key":"2974_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D.A., Orazi, A., Hasserjian, R.P., Borowitz, M.J., Calvo, K.R., Kvasnicka, H.M., Wang, S.A., Bagg, A., Barbui, T., Branford, S., et al. (2022). International Consensus Classification Of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228.","journal-title":"Blood"},{"key":"2974_CR5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41409-023-01970-0","volume":"58","author":"A Baranwal","year":"2023","unstructured":"Baranwal, A., Chhetri, R., Yeung, D., Clark, M., Shah, S., Litzow, M.R., Hogan, W.J., Mangaonkar, A., Alkhateeb, H.B., Singhal, D., et al. (2023). Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant 58, 769\u2013776.","journal-title":"Bone Marrow Transplant"},{"key":"2974_CR6","first-page":"16929","volume":"12","author":"A Belhabri","year":"2023","unstructured":"Belhabri, A., Heiblig, M., Morisset, S., Vila, L., Santana, C., Nicolas-Virelizier, E., Hayette, S., Tigaud, I., Plesa, A., Labussiere-Wallet, H., et al. (2023). Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France. Cancer Med 12, 16929\u201316944.","journal-title":"Real-life experience in a University Hospital and a Cancer Center in France. Cancer Med"},{"key":"2974_CR7","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1002\/cncr.30704","volume":"123","author":"PC Boddu","year":"2017","unstructured":"Boddu, P.C., Kantarjian, H.M., Ravandi, F., Garcia-Manero, G., Verstovsek, S., Jabbour, E.J., Takahashi, K., Bhalla, K., Konopleva, M., DiNardo, C.D., et al. (2017). Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123, 3050\u20133060.","journal-title":"Cancer"},{"key":"2974_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","volume":"52","author":"KL Bolton","year":"2020","unstructured":"Bolton, K.L., Ptashkin, R.N., Gao, T., Braunstein, L., Devlin, S.M., Kelly, D., Patel, M., Berthon, A., Syed, A., Yabe, M., et al. (2020). Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet 52, 1219\u20131226.","journal-title":"Nat Genet"},{"key":"2974_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/j.semdp.2023.04.001","volume":"40","author":"MD Cantu","year":"2023","unstructured":"Cantu, M.D. (2023). Updates in molecular genetics of therapy-related myeloid neoplasms. Semin Diagnostic Pathol 40, 182\u2013186.","journal-title":"Semin Diagnostic Pathol"},{"key":"2974_CR10","doi-asserted-by":"publisher","first-page":"e2200400","DOI":"10.1200\/PO.22.00400","volume":"7","author":"MD Cantu","year":"2023","unstructured":"Cantu, M.D., Kanagal-Shamanna, R., Wang, S.A., Kadia, T., Bueso-Ramos, C.E., Patel, S.S., Geyer, J.T., Tam, W., Madanat, Y., Li, P., et al. (2023). Clinicopathologic and molecular analysis of normal karyotype therapy-related and de novo acute myeloid leukemia: a multi-institutional study by the bone marrow pathology group. JCO Precision Oncol 7, e2200400.","journal-title":"JCO Precision Oncol"},{"key":"2974_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes, J.E., Heidel, F.H., Hellmann, A., Fiedler, W., Smith, B.D., Robak, T., Montesinos, P., Pollyea, D.A., DesJardins, P., Ottmann, O., et al. (2019). Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33, 379\u2013389.","journal-title":"Leukemia"},{"key":"2974_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ajh.23211","volume":"87","author":"R Devillier","year":"2012","unstructured":"Devillier, R., Gelsi-Boyer, V., Brecqueville, M., Carbuccia, N., Murati, A., Vey, N., Birnbaum, D., and Mozziconacci, M. (2012). Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Am J Hematol 87, 659\u2013662.","journal-title":"Am J Hematol"},{"key":"2974_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo, C.D., Pratz, K., Pullarkat, V., Jonas, B.A., Arellano, M., Becker, P.S., Frankfurt, O., Konopleva, M., Wei, A.H., Kantarjian, H.M., et al. (2019). Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133, 7\u201317.","journal-title":"Blood"},{"key":"2974_CR14","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., B\u00fcchner, T., Dombret, H., Ebert, B.L., Fenaux, P., Larson, R.A., et al. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447.","journal-title":"Blood"},{"key":"2974_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","volume":"115","author":"H D\u00f6hner","year":"2010","unstructured":"D\u00f6hner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., B\u00fcchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R.A., et al. (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453\u2013474.","journal-title":"Blood"},{"key":"2974_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H., Wei, A.H., Appelbaum, F.R., Craddock, C., DiNardo, C.D., Dombret, H., Ebert, B.L., Fenaux, P., Godley, L.A., Hasserjian, R.P., et al. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377.","journal-title":"Blood"},{"key":"2974_CR17","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","volume":"123","author":"DA Eichenauer","year":"2014","unstructured":"Eichenauer, D.A., Thielen, I., Haverkamp, H., Franklin, J., Behringer, K., Halbsguth, T., Klimm, B., Diehl, V., Sasse, S., Rothe, A., et al. (2014). Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood 123, 1658\u20131664.","journal-title":"Blood"},{"key":"2974_CR18","doi-asserted-by":"publisher","first-page":"5909","DOI":"10.2147\/OTT.S101333","volume":"11","author":"L Fianchi","year":"2018","unstructured":"Fianchi, L., Criscuolo, M., Fabiani, E., Falconi, G., Maraglino, A.M.E., Voso, M.T., and Pagano, L. (2018). Therapy-related myeloid neoplasms: clinical perspectives. Onco Targets Ther Volume 11, 5909\u20135915.","journal-title":"Onco Targets Ther Volume"},{"key":"2974_CR19","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/ajh.23966","volume":"90","author":"L Fianchi","year":"2015","unstructured":"Fianchi, L., Pagano, L., Piciocchi, A., Candoni, A., Gaidano, G., Breccia, M., Criscuolo, M., Specchia, G., Maria Pogliani, E., Maurillo, L., et al. (2015). Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol 90, E80\u201385.","journal-title":"Am J Hematol"},{"key":"2974_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41409-019-0673-3","volume":"55","author":"KS Gatwood","year":"2020","unstructured":"Gatwood, K.S., Labopin, M., Savani, B.N., Finke, J., Socie, G., Beelen, D., Yakoub-Agha, I., Chevallier, P., Ganser, A., Blaise, D., et al. (2020). Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transplant 55, 224\u2013232.","journal-title":"Bone Marrow Transplant"},{"key":"2974_CR21","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd, L.S., Medeiros, B.C., Sengel\u00f8v, H., N\u00f8rgaard, M., Andersen, M.K., Dufva, I.H., Friis, L.S., Kjeldsen, E., Marcher, C.W., Preiss, B., et al. (2015). Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 33, 3641\u20133649.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2974_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","volume":"2016","author":"M Heuser","year":"2016","unstructured":"Heuser, M. (2016). Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematology 2016(1), 24\u201332.","journal-title":"Hematology"},{"key":"2974_CR23","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser, S., D\u00f6hner, K., Krauter, J., K\u00f6hne, C.H., Horst, H.A., Held, G., von LIlienfeld-Toal, M., Wilhelm, S., K\u00fcndgen, A., G\u00f6tze, K., et al. (2011). The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117, 2137\u20132145.","journal-title":"Blood"},{"key":"2974_CR24","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.3324\/haematol.2019.219352","volume":"105","author":"T Kuzmanovic","year":"2020","unstructured":"Kuzmanovic, T., Patel, B.J., Sanikommu, S.R., Nagata, Y., Awada, H., Kerr, C.M., Przychodzen, B.P., Jha, B.K., Hiwase, D., Singhal, D., et al. (2020). Genomics of therapy-related myeloid neoplasms. Haematologica 105, e98\u2013e101.","journal-title":"Haematologica"},{"key":"2974_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ajh.25395","volume":"94","author":"CJ Lee","year":"2019","unstructured":"Lee, C.J., Labopin, M., Beelen, D., Finke, J., Blaise, D., Ganser, A., It\u00e4l\u00e4-Remes, M., Chevallier, P., Labussi\u00e8re-Wallet, H., Maertens, J., et al. (2019). Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: a report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol 94, 431\u2013438.","journal-title":"Am J Hematol"},{"key":"2974_CR26","first-page":"617","volume":"42","author":"LeukemiaLymphoma Group, Chinese Society of Hematology, Chinese Medical Association.","year":"2021","unstructured":"Leukemia and Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. (2021). Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021) (in Chinese). Chin J Hematol 42, 617\u2013623.","journal-title":"Chin J Hematol"},{"key":"2974_CR27","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood-2009-10-249128","volume":"115","author":"MR Litzow","year":"2010","unstructured":"Litzow, M.R., Tarima, S., P\u00e9rez, W.S., Bolwell, B.J., Cairo, M.S., Camitta, B.M., Cutler, C.S., de Lima, M., DiPersio, J.F., Gale, R.P., et al. (2010). Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115, 1850\u20131857.","journal-title":"Blood"},{"key":"2974_CR28","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.annonc.2021.04.015","volume":"32","author":"JE Martin","year":"2021","unstructured":"Martin, J.E., Khalife-Hachem, S., Grinda, T., Kfoury, M., Garciaz, S., Pasquier, F., Vargaftig, J., Uzunov, M., Belhabri, A., Bertoli, S., et al. (2021). Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. Ann Oncol 32, 1046\u20131048.","journal-title":"Ann Oncol"},{"key":"2974_CR29","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n, D., Meg\u00edas-Vericat, J.E., Serrano, J., Mart\u00ednez-S\u00e1nchez, P., Rodr\u00edguez-Arbol\u00ed, E., Gil, C., Aguiar, E., Bergua, J., L\u00f3pez-Lorenzo, J.L., Bernal, T., et al. (2022). Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv 6, 1278\u20131295.","journal-title":"Blood Adv"},{"key":"2974_CR30","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jtct.2021.08.010","volume":"27","author":"L Metheny","year":"2021","unstructured":"Metheny, L., Callander, N.S., Hall, A.C., Zhang, M.J., Bo-Subait, K., Wang, H.L., Agrawal, V., Al-Homsi, A.S., Assal, A., Bacher, U., et al. (2021). Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther 27, 923.e1\u2013923.e12.","journal-title":"Transplant Cell Ther"},{"key":"2974_CR31","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s11427-024-2666-8","volume":"67","author":"X Mo","year":"2024","unstructured":"Mo, X., Zhang, W., Fu, G., Chang, Y., Zhang, X., Xu, L., Wang, Y., Yan, C., Shen, M., Wei, Q., et al. (2024). Single-cell immune landscape of measurable residual disease in acute myeloid leukemia. Sci China Life Sci 67, 2309\u20132322.","journal-title":"Sci China Life Sci"},{"key":"2974_CR32","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","volume":"121","author":"LM Morton","year":"2013","unstructured":"Morton, L.M., Dores, G.M., Tucker, M.A., Kim, C.J., Onel, K., Gilbert, E.S., Fraumeni Jr, J.F., and Curtis, R.E. (2013). Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008. Blood 121, 2996\u20133004.","journal-title":"Blood"},{"key":"2974_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3324\/haematol.2022.281233","volume":"108","author":"C Nilsson","year":"2023","unstructured":"Nilsson, C., Linde, F., Huleg\u00e5rdh, E., Garelius, H., Lazarevic, V., Antunovic, P., Cammenga, J., Deneberg, S., Eriksson, A., J\u00e4dersten, M., et al. (2023). Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. Haematologica 108, 1015\u20131025.","journal-title":"Haematologica"},{"key":"2974_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/modpathol.2014.160","volume":"28","author":"RS Ohgami","year":"2015","unstructured":"Ohgami, R.S., Ma, L., Merker, J.D., Gotlib, J.R., Schrijver, I., Zehnder, J.L., and Arber, D.A. (2015). Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Modern Pathol 28, 706\u2013714.","journal-title":"Modern Pathol"},{"key":"2974_CR35","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/ajh.23605","volume":"89","author":"MC Ornstein","year":"2014","unstructured":"Ornstein, M.C., Mukherjee, S., Mohan, S., Elson, P., Tiu, R.V., Saunthararajah, Y., Kendeigh, C., Advani, A., Kalaycio, M., Maciejewski, J.P., et al. (2014). Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia. Am J Hematol 89, 168\u2013173.","journal-title":"Am J Hematol"},{"key":"2974_CR36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1600-0609.2010.01464.x","volume":"85","author":"LSG \u00d8stg\u00e5rd","year":"2010","unstructured":"\u00d8stg\u00e5rd, L.S.G., Kjeldsen, E., Holm, M.S., Brown, P.D.N., Pedersen, B.B., Bendix, K., Johansen, P., Kristensen, J.S., and N\u00f8rgaard, J.M. (2010). Reasons for treating secondary AML as de novo AML. Eur J Haematol 85, 217\u2013226.","journal-title":"Eur J Haematol"},{"key":"2974_CR37","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1182\/blood.2022018108","volume":"141","author":"J Othman","year":"2023","unstructured":"Othman, J., Meggendorfer, M., Tiacci, E., Thiede, C., Schlenk, R., Dillon, R., Stasik, S., Venanzi, A., Bertoli, S., Delabesse, E., et al. (2023). Overlapping features of therapy-related and de novo NPM1-mutated AML. Blood 141, 1846\u20131857.","journal-title":"Blood"},{"key":"2974_CR38","doi-asserted-by":"publisher","first-page":"e2023051","DOI":"10.4084\/MJHID.2023.051","volume":"15","author":"R Palmieri","year":"2023","unstructured":"Palmieri, R., Del Principe, I., Maurillo, L., Venditti, A., and Buccisano, F. (2023). Therapy-related myeloid neoplasms: considerations for patients\u2019 clinical evaluation.. Mediterr J Hematol Infect Dis 15, e2023051.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2974_CR39","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/s41409-023-02082-5","volume":"58","author":"G Rey","year":"2023","unstructured":"Rey, G., Daguenet, E., Bonjean, P., Devillier, R., Fegueux, N., Forcade, E., Srour, M., Chevallier, P., Robin, M., Suarez, F., et al. (2023). Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC. Bone Marrow Transplant 58, 1331\u20131338.","journal-title":"Bone Marrow Transplant"},{"key":"2974_CR40","doi-asserted-by":"publisher","first-page":"204062071988282","DOI":"10.1177\/2040620719882822","volume":"10","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier, G., and DiNardo, C.D. (2019). Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol 10, 2040620719882822.","journal-title":"Ther Adv Hematol"},{"key":"2974_CR41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ajh.25814","volume":"95","author":"HJ Rogers","year":"2020","unstructured":"Rogers, H.J., Wang, X., Xie, Y., Davis, A.R., Thakral, B., Wang, S.A., Borthakur, G., Cantu, M.D., Margolskee, E.M., Philip, J.K.S., et al. (2020). Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a bone marrow pathology group study. Am J Hematol 95, 799\u2013808.","journal-title":"Am J Hematol"},{"key":"2974_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","volume":"13","author":"MV Shah","year":"2023","unstructured":"Shah, M.V., Tran, E.N.H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., Shultz, C., Al-Kali, A., Brown, A.L., Chen, D., et al. (2023). TP53 mutation variant allele frequency of \u2a7e10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer J 13, 51.","journal-title":"Blood Cancer J"},{"key":"2974_CR43","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3324\/haematol.2012.076729","volume":"98","author":"AH Shih","year":"2013","unstructured":"Shih, A.H., Chung, S.S., Dolezal, E.K., Zhang, S.J., Abdel-Wahab, O.I., Park, C.Y., Nimer, S.D., Levine, R.L., and Klimek, V.M. (2013). Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Haematologica 98, 908\u2013912.","journal-title":"Haematologica"},{"key":"2974_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/hon.3186","volume":"41","author":"F Tang","year":"2023","unstructured":"Tang, F., Zhao, X., Ruan, G., Jiang, Q., Jiang, H., Xu, L., Wang, Y., Zhang, X., Liu, K., and Huang, X. (2023). The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation. Hematological Oncol 41, 733\u2013742.","journal-title":"Hematological Oncol"},{"key":"2974_CR45","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1186\/s12885-020-07603-9","volume":"20","author":"H Wang","year":"2020","unstructured":"Wang, H., Yin, Y., Wang, R., Huang, J., Xue, H., Cheng, Y., Zhang, L., and Chen, C. (2020). Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia. BMC Cancer 20, 1081.","journal-title":"BMC Cancer"},{"key":"2974_CR46","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei, A.H., Montesinos, P., Ivanov, V., DiNardo, C.D., Novak, J., Laribi, K., Kim, I., Stevens, D.A., Fiedler, W., Pagoni, M., et al. (2020). Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: A phase 3 randomized placebo-controlled trial. Blood 135, 2137\u20132145.","journal-title":"Blood"},{"key":"2974_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/joim.13581","volume":"293","author":"G Weng","year":"2023","unstructured":"Weng, G., Zhang, Y., Yu, G., Luo, T., Yu, S., Xu, N., Sun, Z., Lin, D., Deng, L., Liang, X., et al. (2023). Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med 293, 329\u2013339.","journal-title":"J Intern Med"},{"key":"2974_CR48","first-page":"742","volume":"44","author":"XS Xu","year":"2023","unstructured":"Xu, X.S., Ding, H., Zhang, X., Liao, Y., Li, H., Liu, Q.Y., Liu, J.Z., Zhang, L., Huang, J., Gong, Y.P., et al. (2023). Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors (in Chinese). Chin J Hematol 44, 742\u2013748.","journal-title":"Chin J Hematol"},{"key":"2974_CR49","first-page":"134","volume":"43","author":"WJ Yu","year":"2022","unstructured":"Yu, W.J., Jia, J.S., Wang, J., Tang, F.F., Gong, L.Z., Liu, X.H., Zhu, X.L., Zhao, X.S., Huang, X.J., and Jiang, H. (2022). Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience (in Chinese). Chin J Hematol 43, 134\u2013140.","journal-title":"Chin J Hematol"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2974-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-024-2974-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-024-2974-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:02:53Z","timestamp":1767801773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11427-024-2974-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2974"],"URL":"https:\/\/doi.org\/10.1007\/s11427-024-2974-3","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}